Regeneron Pharmaceuticals Inc. buy phonebroker
Summary
This prediction ended on 20.07.15 with a price of €513.50. The BUY prediction by phonebroker finished with a performance of 11.97%. phonebroker has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | 4.330% | 4.330% | 35.944% | 122.003% |
iShares Core DAX® | -2.926% | -4.228% | 9.878% | 12.466% |
iShares Nasdaq 100 | 4.462% | 8.605% | 33.063% | 59.465% |
iShares Nikkei 225® | 0.306% | 0.284% | 3.871% | 4.557% |
iShares S&P 500 | 2.488% | 4.773% | 27.189% | 50.113% |
Comments by phonebroker for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Spekulativ kaufen
Gute Nachrichtenlage, schöne Kursentwicklung.